Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Kipps, T. J., Swinnen, L. J., Wierda, W. G., Jones, J. A., Coutre, S. E., Smith, M. R., Yang, J., Cui, Y., Busman, T., Enschede, S., Humerickhouse, R. AMER SOC HEMATOLOGY. 2011: 1669–69
View details for Web of Science ID 000299597106074